ANR · ASX

Anatara Lifesciences Ltd (ASX:ANR)

AU$0.057

 0.0 (0.0%)
ASX:Live
15/01/2025 04:10:34 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ANR Overview

ANR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ANR

Website

N/A

Telephone

N/A

Address

Description

Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in Adelaide, Australia.

ANR Price Chart

Key Stats

Market Cap

AU$12.16M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.07

Trade Value (12mth)

AU$1,324.00

1 week

5.56%

1 month

21.28%

YTD

14%

1 year

137.5%

All time high

1.66

Key Fundamentals

EPS 3 yr Growth

-66.40%

EBITDA Margin

N/A

Operating Cashflow

-$1m

Free Cash Flow Return

-109.00%

ROIC

-126.80%

Interest Coverage

N/A

Quick Ratio

5.50

Other Data

Shares on Issue (Fully Dilluted)

181m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ANR Announcements

Latest Announcements

Date Announcements

15 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

24 December 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

24 December 24

Notification regarding unquoted securities - ANR

×

Notification regarding unquoted securities - ANR

23 December 24

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

23 December 24

Addendum to Company Presentation released on 2 December 2024

×

Addendum to Company Presentation released on 2 December 2024

20 December 24

Share Purchase Plan Results

×

Share Purchase Plan Results

13 December 24

GaRP-IBS Clinical Trial Update

×

GaRP-IBS Clinical Trial Update

04 December 24

GaRP-IBS Clinical Trial Update

×

GaRP-IBS Clinical Trial Update

02 December 24

Investor Presentation

×

Investor Presentation

02 December 24

Webinar and Q&A

×

Webinar and Q&A

29 November 24

Company Secretary Appointment/Resignation

×

Company Secretary Appointment/Resignation

27 November 24

Cleansing Notice

×

Cleansing Notice

27 November 24

Share Purchase Plan Offer Booklet

×

Share Purchase Plan Offer Booklet

27 November 24

Share Purchase Plan Shareholder Letter

×

Share Purchase Plan Shareholder Letter

22 November 24

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

22 November 24

Cleansing Notice

×

Cleansing Notice

22 November 24

Change in substantial holding from TEK

×

Change in substantial holding from TEK

22 November 24

Change in substantial holding from Tiga Trading Pty Ltd

×

Change in substantial holding from Tiga Trading Pty Ltd

20 November 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

18 November 24

Notification regarding unquoted securities - ANR

×

Notification regarding unquoted securities - ANR

15 November 24

Successful Placement of $660k and Share Purchase Plan

×

Successful Placement of $660k and Share Purchase Plan

15 November 24

Proposed issue of securities - ANR

×

Proposed issue of securities - ANR

15 November 24

Proposed issue of securities - ANR

×

Proposed issue of securities - ANR

15 November 24

Proposed issue of securities - ANR

×

Proposed issue of securities - ANR

15 November 24

ANR Increase in Placement

×

ANR Increase in Placement

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ANR Shortsell

Frequently Asked Questions

The current share price of Anatara Lifesciences Ltd (ANR:ASX) is AU$0.057.
The 52-week high share price for Anatara Lifesciences Ltd (ANR:ASX) is AU$0.07.
The 52-week low share price for Anatara Lifesciences Ltd (ANR:ASX)? is AU$0.02.
Anatara Lifesciences Ltd (ANR:ASX) does not pay a dividend.
Anatara Lifesciences Ltd (ANR:ASX) does not pay a dividend.
Anatara Lifesciences Ltd (ANR:ASX) has a franking level of 0.0%.
Anatara Lifesciences Ltd (ANR:ASX) is classified in the Healthcare.
The current P/E ratio for Anatara Lifesciences Ltd (ANR:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.